Search

Your search keyword '"Scagliotti, Giorgio"' showing total 1,689 results
Start Over Author "Scagliotti, Giorgio"
1,689 results on '"Scagliotti, Giorgio"'

451. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

Author

Ardizzoni, Andrea, primary, Tiseo, Marcello, additional, Boni, Luca, additional, Di Maio, Massimo, additional, Buffoni, Lucio, additional, Belvedere, Ornella, additional, Grossi, Francesco, additional, D'Alessandro, Vito, additional, de Marinis, Filippo, additional, Barbera, Santi, additional, Caroti, Cinzia, additional, Favaretto, Adolfo, additional, Cortinovis, Diego, additional, Morrica, Brunello, additional, Tixi, Lucia, additional, Ceschia, Tino, additional, Parisi, Salvatore, additional, Ricardi, Umberto, additional, Grimaldi, Andrea, additional, Loreggian, Lucio, additional, Navarria, Pierina, additional, Huber, Rudolf M., additional, Belani, Chandra, additional, Brunsvig, Paal Fr, additional, Scagliotti, Giorgio Vittorio, additional, and Scolaro, Tindaro, additional

Published
2016
Full Text
View/download PDF

452. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy

Author

Tampellini, Marco, primary, Gned, Dario, additional, Baratelli, Chiara, additional, Brizzi, Maria Pia, additional, Ottone, Azzurra, additional, Alabiso, Irene, additional, Bertaggia, Chiara, additional, Di Maio, Massimo, additional, Scagliotti, Giorgio Vittorio, additional, and Veltri, Andrea, additional

Published
2016
Full Text
View/download PDF

454. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Author

Crinò, Lucio, primary, Ahn, Myung-Ju, additional, De Marinis, Filippo, additional, Groen, Harry J.M., additional, Wakelee, Heather, additional, Hida, Toyoaki, additional, Mok, Tony, additional, Spigel, David, additional, Felip, Enriqueta, additional, Nishio, Makoto, additional, Scagliotti, Giorgio, additional, Branle, Fabrice, additional, Emeremni, Chetachi, additional, Quadrigli, Massimiliano, additional, Zhang, Jie, additional, and Shaw, Alice T., additional

Published
2016
Full Text
View/download PDF

457. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Author

Scagliotti, Giorgio, primary, Kang, Jin Hyoung, additional, Smith, David, additional, Rosenberg, Richard, additional, Park, Keunchil, additional, Kim, Sang-We, additional, Su, Wu-Chou, additional, Boyd, Thomas E., additional, Richards, Donald A., additional, Novello, Silvia, additional, Hynes, Scott M., additional, Myrand, Scott P., additional, Lin, Ji, additional, Smyth, Emily Nash, additional, Wijayawardana, Sameera, additional, Lin, Aimee Bence, additional, and Pinder-Schenck, Mary, additional

Published
2016
Full Text
View/download PDF

459. P-202 Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer

Author

Baratelli, C., primary, Sonetto, C., additional, Benedetto, S., additional, Rubatto, E., additional, Di Scipio, F., additional, Pirro, E., additional, Brizzi Maria, P., additional, Di Maio, M., additional, Berta Giovanni, N., additional, Scagliotti Giorgio, V., additional, and Tampellini, M., additional

Published
2016
Full Text
View/download PDF

460. Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.

Author

Felip, Enriqueta, primary, Tan, Daniel Shao-Weng, additional, Kim, Dong-Wan, additional, Mehra, Ranee, additional, Orlov, Sergey, additional, Park, Keunchil, additional, Yu, Chong-Jen, additional, Mok, Tony, additional, Nishio, Makoto, additional, Scagliotti, Giorgio V., additional, Spigel, David R., additional, Sutradhar, Santosh, additional, Cesic, Dajana, additional, and Shaw, Alice Tsang, additional

Published
2016
Full Text
View/download PDF

462. Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).

Author

Scagliotti, Giorgio V., primary, Gaafar, Rabab M., additional, Nowak, Anna K., additional, Van Meerbeeck, Jan P., additional, Vogelzang, Nicholas J., additional, von Wangenheim, Ute, additional, Loembe, Arsene-Bienvenu, additional, Morsli, Nassim, additional, Velema, Derek, additional, and Popat, Sanjay, additional

Published
2016
Full Text
View/download PDF

463. Scientific Advances in Lung Cancer 2015

Author

Tsao, Anne S., primary, Scagliotti, Giorgio V., additional, Bunn, Paul A., additional, Carbone, David P., additional, Warren, Graham W., additional, Bai, Chunxue, additional, de Koning, Harry J., additional, Yousaf-Khan, A. Uraujh, additional, McWilliams, Annette, additional, Tsao, Ming Sound, additional, Adusumilli, Prasad S., additional, Rami-Porta, Ramón, additional, Asamura, Hisao, additional, Van Schil, Paul E., additional, Darling, Gail E., additional, Ramalingam, Suresh S., additional, Gomez, Daniel R., additional, Rosenzweig, Kenneth E., additional, Zimmermann, Stefan, additional, Peters, Solange, additional, Ignatius Ou, Sai-Hong, additional, Reungwetwattana, Thanyanan, additional, Jänne, Pasi A., additional, Mok, Tony S., additional, Wakelee, Heather A., additional, Pirker, Robert, additional, Mazières, Julien, additional, Brahmer, Julie R., additional, Zhou, Yang, additional, Herbst, Roy S., additional, Papadimitrakopoulou, Vassiliki A., additional, Redman, Mary W., additional, Wynes, Murry W., additional, Gandara, David R., additional, Kelly, Ronan J., additional, Hirsch, Fred R., additional, and Pass, Harvey I., additional

Published
2016
Full Text
View/download PDF

465. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung

Author

Righi, Luisella, primary, Vatrano, Simona, additional, Di Nicolantonio, Federica, additional, Massa, Federica, additional, Rossi, Giulio, additional, Cavazza, Alberto, additional, Volante, Marco, additional, Votta, Arianna, additional, Izzo, Stefania, additional, Lo Iacono, Marco, additional, Ardissone, Francesco, additional, Di Maio, Massimo, additional, Novello, Silvia, additional, Scagliotti, Giorgio Vittorio, additional, and Papotti, Mauro, additional

Published
2016
Full Text
View/download PDF

467. Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer

Author

Lo Iacono, Marco, primary, Buttigliero, Consuelo, additional, Monica, Valentina, additional, Bollito, Enrico, additional, Garrou, Diletta, additional, Cappia, Susanna, additional, Rapa, Ida, additional, Vignani, Francesca, additional, Bertaglia, Valentina, additional, Fiori, Cristian, additional, Papotti, Mauro, additional, Volante, Marco, additional, Scagliotti, Giorgio V., additional, Porpiglia, Francesco, additional, and Tucci, Marcello, additional

Published
2016
Full Text
View/download PDF

468. What does the future hold for the Lung Cancer Ambition Alliance project: an interview with Giorgio Scagliotti.

Author

Scagliotti, Giorgio

Abstract

Bio Dr Scagliotti is currently Professor of Oncology at the University of Torino, Italy. Dr Scagliotti earned his medical degree and completed the postgraduate training in respiratory medicine, internal medicine and medical oncology at the University of Torino. He is currently chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), former Head of the Department of Oncology at University of Torino. Dr. Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer (IASLC). From 2003-07 Executive Board Member of the IASLC. He has been Associate Editor for Journal of Thoracic Oncology and currently International Editor for Clinical Lung Cancer. He is the author or co-author of more than 360 publications in peer-reviewed journals and he is the International Editor of the 4th Edition of "Lung Cancer : Principles and practice" and co-editor of the IASLC textbook of multidisciplinary approach to thoracic Oncology. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

471. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Author

Bulik-Sullivan, Brendan, Busby, Jennifer, Palmer, Christine D, Davis, Matthew J, Murphy, Tyler, Clark, Andrew, Busby, Michele, Duke, Fujiko, Yang, Aaron, Young, Lauren, Ojo, Noelle C, Caldwell, Kamilah, Abhyankar, Jesse, Boucher, Thomas, Hart, Meghan G, Makarov, Vladimir, De Montpreville, Vincent Thomas, Mercier, Olaf, Chan, Timothy A, and Scagliotti, Giorgio

Abstract

Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing interest and are in early human trials, but methods to identify neoantigens either require invasive or difficult-to-obtain clinical specimens, require the screening of hundreds to thousands of synthetic peptides or tandem minigenes, or are only relevant to specific human leukocyte antigen (HLA) alleles. We apply deep learning to a large (N = 74 patients) HLA peptide and genomic dataset from various human tumors to create a computational model of antigen presentation for neoantigen prediction. We show that our model, named EDGE, increases the positive predictive value of HLA antigen prediction by up to ninefold. We apply EDGE to enable identification of neoantigens and neoantigen-reactive T cells using routine clinical specimens and small numbers of synthetic peptides for most common HLA alleles. EDGE could enable an improved ability to develop neoantigen-targeted immunotherapies for cancer patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

473. MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression.

Author

Baratelli, Chiara, Tampellini, Marco, Di Maio, Massimo, Ottone, Azzurra, Brizzi, Maria Pia, Forti, Laura, Alabiso, Irene, Sonetto, Cristina, Alabiso, Oscar, and Scagliotti, Giorgio Vittorio

Subjects
COLON cancer treatment, CANCER chemotherapy, PREVENTIVE medicine, CARCINOEMBRYONIC antigen, CANCER invasiveness, CLINICAL trials
Abstract

Background: The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate.Patients and methods: We conducted a multicentre phase II trial assessing the disease control rate (DCR) of the combination of tegafur/uracil and mitomycin C in rmCRC. The number of previous lines of chemotherapy, carcinoembryonic antigen (CEA) levels, progression-free survival of the last chemotherapy regimen (PPFS), and the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio at the time of study entry were evaluated as indicators of early progression.Results: We enrolled 42 patients. The combination was well tolerated with a DCR of 26.2% and median overall survival of 6.9 months. Low CEA levels, PPFS >6 months and low NLR were significantly associated with better prognosis.Conclusion: The study failed its primary endpoint. However, some putative indicators of early progressive patients have been described. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

474. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFRMutation–Positive NSCLC Patients

Author

Scagliotti, Giorgio, Moro-Sibilot, Denis, Kollmeier, Jens, Favaretto, Adolfo, Cho, Eun Kyung, Grosch, Heidrun, Kimmich, Martin, Girard, Nicolas, Tsai, Chun-Ming, Hsia, Te-Chun, Brighenti, Matteo, Schumann, Christian, Wang, Xuejing Aimee, Wijayawardana, Sameera R., Gruver, Aaron M., Wallin, Johan, Mansouri, Kambiz, Wacheck, Volker, and Chang, Gee-Chen

Abstract

The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.

Published
2020
Full Text
View/download PDF

475. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells

Author

Rapa Ida1, Volante Marco1, Migliore Cristina2, Farsetti Antonella3,4, Berruti Alfredo1, Scagliotti Giorgio Vittorio1, Giordano Silvia2, and Papotti Mauro1

Subjects
Male, androgen deprivation, Prostate Cancer, Neuroendocrine Differentiation, Prostatic Neoplasms, Cell Differentiation, hASH-1, prostate cancer, neuroendocrine differentiation, Neurosecretory Systems, Cell Line, Tumor, Androgens, Basic Helix-Loop-Helix Transcription Factors, Humans, Cell Line, Transformed
Abstract

BACKGROUND: Neuroendocrine differentiation in prostate cancer is a dynamic process associated to the onset of hormone-refractory disease in vivo. The molecular mechanisms underlying this process are poorly recognized. Our study aimed at testing in vitro the role of hASH-1, a transcription factor implicated in neuroendocrine differentiation, in the onset of neuroendocrine phenotype in prostate cancer cells. METHODS: Androgen sensitive LNCAP, androgen insensitive PC-3, and three immortalized prostate cancer cell lines were cultured in standard and androgen deprivation conditions. Expression of hASH-1 was modulated by either specific lentiviral transduction or shRNA interference. Inhibitors of WNT-11, a WNT family member associated to the development of neuroendocrine differentiation in prostate cancer, were also used. Cell viability was measured using the MTS method. Neuroendocrine phenotype was assessed by morphology, immunohistochemistry and real time PCR for several neuroendocrine markers. RESULTS: hASH-1 was up-modulated by androgen deprivation in LNCaP cells and in androgen-sensitive immortalized prostate cancer cells, and associated with the onset of a neuroendocrine phenotype. Silencing of hASH-1 prevented neuroendocrine differentiation, as did also the selective interference with the WNT-11 pathway. Moreover, hASH-1 over-expression in LNCaP cells was sufficient to promote neuroendocrine differentiation and increased cell viability at basal and androgen-deprived growth conditions. CONCLUSION: In summary, the present data support previous evidence that the acquisition of a neuroendocrine phenotype is linked to androgen responsiveness profiles and suggest a pivotal role of hASH-1 transcription factor, whose activity might be explored as a potential therapeutic target in prostate cancer, with special reference to hormone refractory disease.

Published
2013
Full Text
View/download PDF

478. P-202 Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer

Author

E. Rubatto, M. Di Maio, Elisa Pirro, Marco Tampellini, F Di Scipio, Simone Benedetto, Cristina Sonetto, N. Berta Giovanni, Chiara Baratelli, P. Brizzi Maria, and V. Scagliotti Giorgio

Subjects
Oncology, medicine.medical_specialty, Therapeutic equivalency, Colorectal cancer, business.industry, Incidence (epidemiology), Hematology, Bioequivalence, medicine.disease, Oxaliplatin, Advanced colorectal cancer, Abstracts, Internal medicine, medicine, In patient, business, medicine.drug
Published
2016
Full Text
View/download PDF

481. Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study

Author

Behera, Madhusmita, Jiang, Renjian, Huang, Zhonglu, Bunn, Becky, Wynes, Murry W., Switchenko, Jeffrey, Scagliotti, Giorgio V., Belani, Chandra P., and Ramalingam, Suresh S.

Abstract

Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations account for approximately 10% of EGFR mutations in lung adenocarcinoma. Patients with ex20ins mutation do not respond to standard EGFR TKI therapy. In this work, we analyzed the characteristics, treatment patterns and outcomes in this subgroup of NSCLC patients.

Published
2024
Full Text
View/download PDF

482. Hormonal agents in localized and advanced prostate cancer: current use and future perspectives.

Author

Turco, Fabio, Buttigliero, Consuelo, Delcuratolo, Marco Donatello, Gillessen, Silke, Vogl, Ursula Maria, Zilli, Thomas, Fossati, Nicola, Gallina, Andrea, Farinea, Giovanni, Stefano, Rosario Francesco Di, Calabrese, Mariangela, Saporita, Isabella, Crespi, Veronica, Poletto, Stefano, Palesandro, Erica, Maio, Massimo Di, Scagliotti, Giorgio Vittorio, and Tucci, Marcello

Abstract

Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy (ADT) has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.

Published
2024
Full Text
View/download PDF

483. Contributors

Author

Adjei, Alex A., Ahn, Mjung-Ju, Amos, Chris I., Antonicelli, Alberto, Asamura, Hisao, Atwood, Todd, Baas, Paul, Bailey-Wilson, Joan E., Ball, David, Barlesi, Fabrice, Bazan, Jose G., Belderbos, José, Bezjak, Andrea, Billingham, Lucinda J., Boffetta, Paolo, Bonifazi, Martina, Brahmer, Julie R., Brambilla, Elisabeth, Brims, Fraser, Brunelli, Alessandro, Bryant, Ayesha, Campbell, Nicholas, Carter, Brett W., Cerfolio, Robert, Cho, Byoung Chul, Cho, William C.S., Choy, Hak, Chu, Chia-Yu, Colburn, Glenda, Colt, Henri, Rosell Costa, Rafael, Darling, Gail E., Davis, Mellar, de Groot, Patricia M., de Koning, Harry J., De Leyn, Paul, De Ruysscher, Dirk, Demiral, Ayşe Nur, Derks, Jules, Detterbeck, Frank C., Devarakonda, Siddhartha, Dingemans, Anne-Marie C., Donington, Jessica S., Dresler, Carolyn M., Dubinett, Steven M., Dy, Grace K., Erasmus, Jeremy J., Fairchild, Alysa, Fennell, Dean A., Fernando, Hiran C., Filosso, Pier Luigi, Flores, Raja, Fong, Kwun, Fox, Jesme, Gandara, David R., Gandhi, Leena, Gaspar, Laurie, Gasparini, Stefano, Gazdar, Adi F., Giaccone, Giuseppe, Girard, Nicolas, Goldstraw, Peter, Gore, Elizabeth M., Goss, Glenwood, Govindan, Ramaswamy, Greenberg, Alissa K., Grunenwald, Dominique, Guckenberger, Matthias, Gulati, Swati, Hassan, Raffit, Hazzard, Christopher, Hegi, Fiona, Hensing, Thomas, Herbst, Roy, Hirsch, Fred R., Horeweg, Nanda, Jablons, David M., Jett, James R., Kaufman, Andrew, Keall, Paul, Kelly, Karen, Kong, Feng-Ming (Spring), Kubota, Kaoru, Laird-Offringa, Ite A., Lara, Primo N., Jr, Laskin, Janessa, Le, Quynh-Thu, Le Péchoux, Cécile, Liclican, Elvira L., Lievens, Yolande, Lin, Chia-Chi (Josh), Loo, Billy W., Jr., Manus, Michael Mac, Macapinlac, Homer A., Macbeth, Fergus, Mackillop, William J., Maher, Christopher, Mambetsariev, Isa, Mandrekar, Sumithra J., Mansfield, Aaron S., Marks, Lawrence B., Mascaux, Céline, Massion, Pierre P., Mazieres, Julien, McWilliams, Annette, Mitsudomi, Tetsuya, Mok, Tony, Morgensztern, Daniel, Mornex, Francoise, Mulshine, James L., Munden, Reginald F., Nackaerts, Kristiaan, Nakamichi, Shinji, Noguchi, Masayuki, Noonan, Krista, Novello, Silvia, Nowak, Anna K., O’Byrne, Kenneth J., Ohri, Nisha, Okada, Morihito, Ostroff, Jamie S., Parikh, Mamta, Park, Elyse R., Park, Keunchil, Pass, Harvey I., Pastis, Nicholas, Paz-Ares, Luis, Pennell, Nathan, Perol, Maurice, Pillai, Rathi N., Postmus, Pieter E., Ramalingham, Suresh S., Ramella, Sara, Rami-Porta, Ramón, Reck, Martin, Redman, Mary W., Reinmuth, Niels, Ricardi, Umberto, Rice, David, Ridge, Carole A., Rom, William N., Rosenzweig, Kenneth E., Ruffini, Enrico, Rusch, Valerie W., Salgia, Ravi, Sanchez-Cespedes, Montse, Saqi, Anjali, Scagliotti, Giorgio V., Schimmel, Selma, Schwartz, Ann G., Senan, Suresh, Shepherd, Francis A., Siegfried, Jill M., Silvestri, Gerard A., Simon, George R., Smit, Egbert F., Solomon, Stephen B., Stabile, Laura P., Steliga, Matthew A., Stinchcombe, Thomas E., Stollenwerk, Nicholas S., Sun, Jong-Mu, Thomas, Anish, Tsao, Ming-Sound, Tsay, Jun-Chieh J., Van Houtte, Paul, Van Schil, Paul E., van Zandwijk, Nico, Vansteenkiste, J.F., Varella-Garcia, Marileila, Veronesi, Giulia, Vinod, Shalini K., Vokes, Everett E., Wakelee, Heather, Walser, Tonya C., Watanabe, Shun-ichi, Weder, Walter, Wei, Benjamin, Wistuba, Ignacio I., Yang, James Chih-Hsin, Yankelevitz, David F., Yasufuku, Kazuhiro, Yoneda, Ken Y., Zalcman, Gérard, Zhou, Caicun, Zhou, Yang, and Zips, Daniel

Published
2018
Full Text
View/download PDF

484. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.

Author

Iuliani, Michele, Pantano, Francesco, Buttigliero, Consuelo, Fioramonti, Marco, Bertaglia, Valentina, Vincenzi, Bruno, Zoccoli, Alice, Ribelli, Giulia, Tucci, Marcello, Vignani, Francesca, Berruti, Alfredo, Scagliotti, Giorgio Vittorio, Tonini, Giuseppe, Santini, Daniele, Iuliani, Michele, Pantano, Francesco, Buttigliero, Consuelo, Fioramonti, Marco, Bertaglia, Valentina, Vincenzi, Bruno, Zoccoli, Alice, Ribelli, Giulia, Tucci, Marcello, Vignani, Francesca, Berruti, Alfredo, Scagliotti, Giorgio Vittorio, Tonini, Giuseppe, and Santini, Daniele

Abstract

Abiraterone acetate (ABI) is associated not only with a significant survival advantage in both chemotherapy-naive and -treated patients with metastatic castration-resistant prostate cancer (mCRPC), but also with a delay in time to development of Skeletal Related Events and in radiological skeletal progression. These bone benefits may be related to a direct effect on prostate cancer cells in bone or to a specific mechanism directed to bone microenvironment. To test this hypothesis we designed an in vitro study aimed to evaluate a potential direct effect of ABI on human primary osteoclasts/osteoblasts (OCLs/OBLs). We also assessed changes in bone turnover markers, serum carboxy-terminal collagen crosslinks (CTX) and alkaline phosphatase (ALP), in 49 mCRPC patients treated with ABI.Our results showed that non-cytotoxic doses of ABI have a statistically significant inhibitory effect on OCL differentiation and activity inducing a down-modulation of OCL marker genes TRAP, cathepsin K and metalloproteinase-9. Furthermore ABI promoted OBL differentiation and bone matrix deposition up-regulating OBL specific genes, ALP and osteocalcin. Finally, we observed a significant decrease of serum CTX values and an increase of ALP in ABI-treated patients.These findings suggest a novel biological mechanism of action of ABI consisting in a direct bone anabolic and anti-resorptive activity., info:eu-repo/semantics/published

Published
2015

485. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

Author

Iuliani, Michele, primary, Pantano, Francesco, additional, Buttigliero, Consuelo, additional, Fioramonti, Marco, additional, Bertaglia, Valentina, additional, Vincenzi, Bruno, additional, Zoccoli, Alice, additional, Ribelli, Giulia, additional, Tucci, Marcello, additional, Vignani, Francesca, additional, Berruti, Alfredo, additional, Scagliotti, Giorgio Vittorio, additional, Tonini, Giuseppe, additional, and Santini, Daniele, additional

Published
2015
Full Text
View/download PDF

487. Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study

Author

Scagliotti, Giorgio V., primary, Orlov, Sergey, additional, von Pawel, Joachim, additional, Shepherd, Frances A., additional, Akerley, Wallace, additional, Ross, Jeffrey S., additional, Shuster, Dale, additional, Wang, Qiang, additional, Schwartz, Brian, additional, and von Roemeling, Reinhard, additional

Published
2015
Full Text
View/download PDF

491. Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker

Author

Ramlau, Rodryg, primary, Thomas, Michael, additional, Novello, Silvia, additional, Plummer, Ruth, additional, Reck, Martin, additional, Kaneko, Tomomi, additional, Lau, Mike R., additional, Margetts, Jane, additional, Lunec, John, additional, Nutt, Joyce, additional, and Scagliotti, Giorgio V., additional

Published
2015
Full Text
View/download PDF

492. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Author

Scagliotti, Giorgio, primary, von Pawel, Joachim, additional, Novello, Silvia, additional, Ramlau, Rodryg, additional, Favaretto, Adolfo, additional, Barlesi, Fabrice, additional, Akerley, Wallace, additional, Orlov, Sergey, additional, Santoro, Armando, additional, Spigel, David, additional, Hirsh, Vera, additional, Shepherd, Frances A., additional, Sequist, Lecia V., additional, Sandler, Alan, additional, Ross, Jeffrey S., additional, Wang, Qiang, additional, von Roemeling, Reinhard, additional, Shuster, Dale, additional, and Schwartz, Brian, additional

Published
2015
Full Text
View/download PDF

494. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).

Author

Mok, Tony, primary, Spigel, David, additional, Felip, Enriqueta, additional, deMarinis, Filippo, additional, Ahn, Myung-Ju, additional, Groen, Harry J.M., additional, Wakelee, Heather A., additional, Hida, Toyoaki, additional, Crino, Lucio, additional, Nishio, Makoto, additional, Scagliotti, Giorgio V., additional, Branle, Fabrice, additional, Emeremni, Chetachi, additional, Quadrigli, Massimiliano, additional, Zhang, Jie, additional, and Shaw, Alice Tsang, additional

Published
2015
Full Text
View/download PDF

495. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).

Author

Felip, Enriqueta, primary, Orlov, Sergey, additional, Park, Keunchil, additional, Yu, Chong-Jen, additional, Tsai, Chun-Ming, additional, Nishio, Makoto, additional, Cobo Dols, Manuel, additional, McKeage, Mark James, additional, Su, Wu-Chou, additional, Mok, Tony, additional, Scagliotti, Giorgio V., additional, Spigel, David, additional, Branle, Fabrice, additional, Emeremni, Chetachi, additional, Quadrigli, Massimiliano, additional, and Shaw, Alice Tsang, additional

Published
2015
Full Text
View/download PDF

496. Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine.

Author

Bepler, Gerold, primary, Chen, Wei, additional, Patrick, Stephan, additional, Astrow, Stephanie H., additional, Stephens, Craig, additional, Gandara, David R., additional, Rosell, Rafael, additional, Ramirez, Jose Luis, additional, Scagliotti, Giorgio V., additional, Busso, Simone, additional, Volante, Marco, additional, and Novello, Silvia, additional

Published
2015
Full Text
View/download PDF

497. Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis.

Author

Tucci, Marcello, primary, Vignani, Francesca, additional, Bertaglia, Valentina, additional, Buttigliero, Consuelo, additional, Berruti, Alfredo, additional, Scagliotti, Giorgio V., additional, and Di Maio, Massimo, additional

Published
2015
Full Text
View/download PDF

498. Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

Author

Lo Iacono, Marco, primary, Monica, Valentina, additional, Righi, Luisella, additional, Grosso, Federica, additional, Libener, Roberta, additional, Vatrano, Simona, additional, Bironzo, Paolo, additional, Novello, Silvia, additional, Musmeci, Loredana, additional, Volante, Marco, additional, Papotti, Mauro, additional, and Scagliotti, Giorgio V., additional

Published
2015
Full Text
View/download PDF

499. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial

Author

Yang, Ch, Simms, L, Park, K, Lee, Js, Scagliotti, Giorgio Vittorio, Graduate Institute of Oncology, Orlando M., National Taiwan University Hospital, and Taipei, Taiwan

Subjects
Pulmonary and Respiratory Medicine, Oncology, Adult, Male, medicine.medical_specialty, Guanine, Lung Neoplasms, Subgroup analysis, Pemetrexed, Adenocarcinoma, Deoxycytidine, Glutamates, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Survival rate, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Proportional hazards model, business.industry, International Agencies, Middle Aged, medicine.disease, Gemcitabine, Surgery, Clinical trial, Survival Rate, Treatment Outcome, Carcinoma, Squamous Cell, Population study, Carcinoma, Large Cell, Female, Cisplatin, Safety, business, medicine.drug
Abstract

Introduction We conducted an exploratory, post hoc, subgroup analysis of the East Asian (EA) patients in a multinational phase III trial to determine whether the efficacy results for this subgroup were consistent with those observed for the entire study population. Methods Thousand seven hundred twenty-five patients with advanced non-small cell lung cancer (NSCLC), including 126 EA patients (7.3%) from Taiwan and Korea, were enrolled in the trial and randomly assigned first-line chemotherapy with cisplatin and pemetrexed (CP; n = 862) or cisplatin and gemcitabine (CG; n = 863). Adjusted Cox proportional hazards models were used to compare overall survival and progression-free survival between the treatment arms in the EA subgroup. Median time-to-event data were estimated with the Kaplan-Meier method. Results Consistent with the results for the entire study population, survival in the EA subgroup trended in favor of CP over CG in patients with nonsquamous histology, despite the more frequent use of postdiscontinuation targeted therapy in the CG arm. The opposite trend was noted for patients with squamous tumors. A higher proportion of patients in the EA subgroup were never smokers compared with the entire study population. A trend toward improved survival with CP compared with CG was seen regardless of smoking status, particularly in nonsquamous patients. Conclusions The key finding of this subgroup analysis was that the NSCLC histology effect on treatment outcomes for pemetrexed-treated patients seen in the entire study population was also apparent in the EA subgroup. The potential prognostic influence of race, histology subtype, and smoking status should be assessed in future NSCLC studies.

Published
2010

500. Histologic subtype in NSCLC: does it matter?

Author

Selvaggi, G and Scagliotti, Giorgio Vittorio

Subjects
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Antineoplastic Agents, Neoplasm Staging
Abstract

Platinum-based doublet chemotherapy remains the cornerstone of therapy in the first-line setting in advanced non-small-cell lung cancer (NSCLC) for patients with good performance status. However, this paradigm has recently been challenged by the results of a study that showed a survival benefit with the addition of bevacizumab to carboplatin and paclitaxel in bevacizumab-eligible patients and by the superior efficacy of gefitinib and erlotinib compared to chemotherapy in epidermal growth factor receptor (EGFR) gene mutation-positive tumors (mainly adenocarcinomas). In addition, histology has been recently recognized as a potential predictive factor in advanced NSCLC patients treated with chemotherapy. Prospective data from a preplanned subgroup analysis of a phase III study and retrospective reviews consistently reported a significant interaction between treatment by histology and response/survival in nonsquamous NSCLCs treated with pemetrexed, compared to squamous cell carcinoma (SCC). Thymidylate synthase, the main target of pemetrexed, was found to be differentially expressed among the histotypes of lung cancer, being lower in adenocarcinoma and higher in SCC and small-cell lung cancer. Thus, the availability of adequate amounts of tissue from biopsies to allow accurate pathologic subclassifications at diagnosis will be critical to help the oncologist select the most appropriate chemotherapy regimen as we move toward an individualized molecularly based approach.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results